FBRX NASDAQ
Forte Biosciences, Inc.
1W: +0.1%
1M: +0.6%
3M: +270.7%
YTD: +226.1%
1Y: +583.8%
3Y: +271.0%
5Y: -88.1%
$76.99
Last traded 2026-08-28 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.6B
52W Range10.11-77.2
Volume0
Avg Volume998,503
Beta2.65
Dividend—
Analyst Ratings
Company Info
CEOPaul A. Wagner
Employees23
SectorHealthcare
IndustryBiotechnology
IPO Date2017-04-13
Websitefortebiorx.com
3060 Pegasus Park Drive
Dallas, TX 75247
US
Dallas, TX 75247
US
310 618 6994
About Forte Biosciences, Inc.
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
Latest News
Squarepoint Ops LLC Reduces Position in Forte Biosciences, Inc. $FBRX
Bank of New York Mellon Corp Makes New Investment in Forte Biosciences, Inc. $FBRX
Bank of America Corp DE Has $560,000 Holdings in Forte Biosciences, Inc. $FBRX
Forte Biosciences, Inc. (NASDAQ:FBRX) Receives $72.50 Average Target Price from Brokerages
Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| FINCK BARBARA K | D-Return | 2,000 | $35.75 | 2026-08-27 |
| FINCK BARBARA K | D-Return | 166 | $35.75 | 2026-08-27 |
| FINCK BARBARA K | D-Return | 1,000 | $31.75 | 2026-08-27 |
| FINCK BARBARA K | D-Return | 1,000 | $20.00 | 2026-08-27 |
| FINCK BARBARA K | D-Return | 7,000 | $17.25 | 2026-08-27 |